-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathhealth.html
1253 lines (1236 loc) · 51.9 KB
/
health.html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
<!doctype html>
<title>Health</title>
<script>
function rgb2hsv (r, g, b) {
let rabs, gabs, babs, rr, gg, bb, h, s, v, diff, diffc, percentRoundFn;
rabs = r / 255;
gabs = g / 255;
babs = b / 255;
v = Math.max(rabs, gabs, babs),
diff = v - Math.min(rabs, gabs, babs);
diffc = c => (v - c) / 6 / diff + 1 / 2;
percentRoundFn = num => Math.round(num * 100) / 100;
if (diff == 0) {
h = s = 0;
} else {
s = diff / v;
rr = diffc(rabs);
gg = diffc(gabs);
bb = diffc(babs);
if (rabs === v) {
h = bb - gg;
} else if (gabs === v) {
h = (1 / 3) + rr - bb;
} else if (babs === v) {
h = (2 / 3) + gg - rr;
}
if (h < 0) {
h += 1;
}else if (h > 1) {
h -= 1;
}
}
return {
h: Math.round(h * 360),
s: percentRoundFn(s * 100),
v: percentRoundFn(v * 100)
};
}
function isGreen(r,g,b){
h = rgb2hsv(r,g,b).h;
if(h >= 69 && h <= 181){
return (true);
}
return false;
}
function hexToRgb(hex) {
var result = /^#?([a-f\d]{2})([a-f\d]{2})([a-f\d]{2})$/i.exec(hex);
return result ? {
r: parseInt(result[1], 16),
g: parseInt(result[2], 16),
b: parseInt(result[3], 16)
} : null;
}
function getRandomColor() {
var letters = '0123456789ABCDEF';
var color = '#';
for (var i = 0; i < 6; i++) {
color += letters[Math.floor(Math.random() * 16)];
}
var colors = hexToRgb(color);
if(isGreen(colors.r,colors.g,colors.b)){
return getRandomColor();
}
return color;
}
function graph(t){
t.style.borderCollapse='collapse';
t=t.rows[0];
for(var i=0;i<t.children.length;i++){
t.children[i].style.textAlign = 'center';
t.children[i].innerHTML = "<div style='display:inline-block;background:"+getRandomColor()+";width:20px;height:"+t.children[i].innerHTML+"px'></div><br>"+t.children[i].innerHTML;
t.children[i].style.verticalAlign = 'bottom';
}
}
window.onload = function(){
var t = document.getElementsByClassName('bargraph');
for(var i=0;i<t.length;i++)graph(t[i]);
}
</script><pre>
Who gives deliveries in the delivery room female nurses
and female doctors
Zyprexa->Serouel->Risperdal->Abilify Maintena
Patrick Soon-Shiong $7.3 billion
Thomas Frist $4 billion
Gayle Cook $3.7 billion
Ronda Stryker $2.5 billion
Faulkner $1.7 billion
<a href="https://www.athenahealth.com/insight/healthcare-future-female">Healthcare future is female</a>
<a href="https://www.statista.com/chart/14983/female-doctors-by-country/">Female Doctors By Country</a>
<h1>Health Care</h1><p>
How do I make any supplement into liquid?
<a href="https://hitconsultant.net/wp-content/uploads/2014/07/Top-5-Most-Widely-Used-EHRs-by-Physicians.jpg">PhysiciansEMR</a>
</p>
<a href="https://en.wikipedia.org/wiki/Richmond_Agitation-Sedation_Scale">RASS</a>
<img src="https://stahlonline.cambridge.org/content/ep4/images/02598fig5_7.png" width=400>
Names of antipsychotics | nuerotoxins, antipsychotics, neuroleptics
extrapyramidal symptoms include acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome
<a href="http://clincalc.com/PronounceTop200Drugs/">Top Drugs</a>
<table summary="Results - COMPREHENSIVE METABOLIC PANEL - Final result (04/13/2018 11:41 AM)">
<colgroup>
<col style="width:25%">
<col style="width:50%">
<col style="width:25%">
</colgroup>
<thead>
<tr class="SRonly">
<th colspan="3" scope="colgroup">COMPREHENSIVE METABOLIC PANEL - Final result (04/13/2018 11:41 AM)</th>
</tr>
<tr>
<th>Component</th>
<th>Value</th>
<th>Ref Range</th>
</tr>
</thead>
<tbody>
<tr class="TableRow" id="Result434017075Comp1">
<td id="Result434017075Comp1Name">Sodium(na)</td>
<td>138</td>
<td>135 - 146 MMOL/L</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp2">
<td id="Result434017075Comp2Name">Potassium(k)</td>
<td><span>4.1</span><span class="allIndent"><span class="cellHeader">Comment: </span><span id="Result434017075Comp2Comment">NO VISIBLE HEMOLYSIS</span></span></td>
<td>3.5 - 5.3 MMOL/L</td>
</tr>
<tr class="TableRow" id="Result434017075Comp3">
<td id="Result434017075Comp3Name">Chloride(chloide)</td>
<td>104</td>
<td>98 - 110 MMOL/L</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp4">
<td id="Result434017075Comp4Name">CO2</td>
<td>26</td>
<td>21 - 33 MMOL/L</td>
</tr>
<tr class="TableRow" id="Result434017075Comp5">
<td id="Result434017075Comp5Name">BUN
<br>Blood urea nitrogen
<div data-local-attribute="d3bn" data-ved="2ahUKEwiv-N6J4LzcAhUS2lMKHe7SBXEQ3B0oATAeegQICxAN"></div>
</td>
<td>15</td>
<td>8 - 24 MG/DL</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp6">
<td id="Result434017075Comp6Name">Glucose(C<sub>6</sub>H<sub>12</sub>O<sub>6)</sub></td>
<td>85</td>
<td>70 - 99 MG/DL</td>
</tr>
<tr class="TableRow" id="Result434017075Comp7">
<td id="Result434017075Comp7Name">Creatinine</td>
<td>0.98</td>
<td>0.50 - 1.50 MG/DL</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp8">
<td id="Result434017075Comp8Name">Calcium(Ca)</td>
<td>9.7</td>
<td>8.5 - 10.5 MG/DL</td>
</tr>
<tr class="TableRow" id="Result434017075Comp9">
<td id="Result434017075Comp9Name">Total Protein</td>
<td>7.0</td>
<td>6.0 - 8.3 G/DL</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp10">
<td id="Result434017075Comp10Name">Albumin </td>
<td>4.7</td>
<td>3.5 - 5.0 G/DL</td>
</tr>
<tr class="TableRow" id="Result434017075Comp11">
<td id="Result434017075Comp11Name">Total Bilirubin</td>
<td>0.5</td>
<td>0.1 - 1.2 MG/DL</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp12">
<td id="Result434017075Comp12Name">Alkaline Phosphatase</td>
<td>53</td>
<td>25 - 125 IU/L</td>
</tr>
<tr class="TableRow" id="Result434017075Comp13">
<td id="Result434017075Comp13Name">AST (SGOT)</td>
<td>21</td>
<td>5 - 40 IU/L</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp14">
<td id="Result434017075Comp14Name">ALT (SGPT)</td>
<td>36</td>
<td>5 - 50 IU/L</td>
</tr>
<tr class="TableRow" id="Result434017075Comp15">
<td id="Result434017075Comp15Name">Anion Gap</td>
<td>8</td>
<td>4 - 14 MMOL/L</td>
</tr>
<tr class="alt TableRow" id="Result434017075Comp16">
<td id="Result434017075Comp16Name">Est. GFR Non-Black</td>
<td><span>>60</span><br><span class="allIndent"><span class="cellHeader">Comment: </span><br><span class="monospace" id="Result434017075Comp16Comment"><br>GFR is calculated by IDMS traceable MDRD method, and the result is about 5% lower than previously reported results (prior to Dec 12, 2011).<br></span></span></td>
<td> </td>
</tr>
<tr id="Result434017075Comp17">
<td id="Result434017075Comp17Name">Est. GFR Black</td>
<td><span>>60</span><br><span class="allIndent"><span class="cellHeader">Comment: </span><br><span class="monospace" id="Result434017075Comp17Comment"><br>GFR is calculated by IDMS traceable MDRD method, and the result is about 5% lower than previously reported results (prior to Dec 12, 2011).<br></span></span></td>
<td> </td>
</tr>
<tr id="Result405894532Comp1">
<td id="Result405894532Comp1Name">Triglycerides</td>
<td>324 (01/15/2016)</td>
<td><150 MG/DL</td>
</tr>
</tbody>
</table>
<div>OCT 02 2017</div><a href="https://www.labcorp.com/help/patient-test-info/thyroid-panel">Thyroid Panels</a><pre>
Cholesterol, Total 105NORMAL
Triglycerides 137NORMAL
HDL Cholesterol 28
VLDL Cholesterol Cal 27
LDL Cholesterol Calc 50</pre>
<table><thead><tr><th>TSH</th><th>T4</th><th>T3</th><th>Interpretation</th></tr></thead><tbody><tr><td>High</td>
<td>Normal</td>
<td>Normal</td>
<td>Mild (subclinical) hypothyroidism</td>
</tr><tr><td>High</td>
<td>Low</td>
<td>Low or normal</td>
<td>Hypothyroidism</td>
</tr><tr><td>Low</td>
<td>Normal</td>
<td>Normal</td>
<td>Mild (subclinical) hyperthyroidism</td>
</tr><tr><td>Low</td>
<td>High or normal</td>
<td>High or normal</td>
<td>Hyperthyroidism</td>
</tr><tr><td>Low</td>
<td>Low or normal</td>
<td>Low or normal</td>
<td>Nonthyroidal illness; pituitary (secondary) hypothyroidism</td>
</tr><tr><td>Normal</td>
<td>High</td>
<td>High</td>
<td>Thyroid hormone resistance syndrome (a mutation in the thyroid hormone receptor decreases thyroid hormone function)</td>
</tr></tbody></table>
<p>Pet Scan radioactive particles vs MRI scan</p>
<p><b>10 Most Prescribed Psychiatric Drugs in the the U.S. (in millions)</b></p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>44</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>18</td>
<td>19</td>
<td>19</td>
<td>27</td>
<td>14</td>
</tr>
<tr>
<td>Xanax</td>
<td>Valium/<br>
Diazepam</td>
<td>Seroquel<br>
(antipsychotic)</td>
<td>Cymbalta<br>(antidepressant)</td>
<td>Trazodone<br>(antidepressant)</td>
<td>Prozac</td>
<td>Zoloft</td>
<td>Lexapro</td>
<td>Effexor</td>
</tr>
</table>
<p><b>Top 10 Psychiatric Drugs by primary mechanism</b></p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>15</td>
<td>66</td>
<td>31</td>
<td>83</td>
<td>18</td>
</tr>
<tr>
<td>Antipsychotic</td>
<td>SSRI</td>
<td>SNRI</td>
<td>Benzo-diazepene</td>
<td>5-T2A Blocker & SSRI</td>
</tr>
</table>
<p><b>Weight gain from antipsychotic drugs after 2.5 months (in pounds)</b></p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>-2.0</td>
<td>-.7</td>
<td>.2</td>
<td>.9</td>
<td>1.5</td>
<td>1.9</td>
<td>2.4</td>
<td>4.6</td>
<td>5.0</td>
<td>6.5</td>
<td>7.0</td>
<td>9.2</td>
<td>9.9</td>
</tr>
<tr>
<td>Placebo</td>
<td>Moban</td>
<td>Geodon</td>
<td>Permitil</td>
<td>Abilify</td>
<td>Solian</td>
<td>Haldol</td>
<td>Risperdal</td>
<td>Seroquel</td>
<td>Serdolect</td>
<td>Thorazine</td>
<td>Zyprexa</td>
<td>Clozapine</td>
</tr>
</table>
<p><b>Most common medications for bipolar</b></p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>70.9</td>
<td>53</td>
<td>.30</td>
<td>.8</td>
<td>5.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Mood Stabalizers</td>
<td>Antipsychotics</td>
<td>Antidepressants</td>
<td>Anxiety</td>
<td>Sleep</td>
<td>Other</td>
</tr>
</table>
<p>Tardive Dyskinesia risk</p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>39</td>
<td>53</td>
</tr>
<tr>
<td>atypical</td>
<td>(out of 100%)typical</td>
</tr>
</table>
<p>qtc</p>
<p>PCOS Polycystic ovary syndrome</p>
<img src=https://i.stack.imgur.com/ygsV9.png>
<p>Sedation
</p><p>
Qt interval prolongation
<ol>
<li>Cardiac conditions such as bradycardia, myocardial infarction, or hearth failure</li>
<li>Electrolyte distirbuances</li>
<li>Female sex</li>
<li>Genetic Polymorphisms</li>
<li>Age older then 65 years old</li>
<li>Congentital long QT syndrome or other inherited cardiac abnormalities</li>
<li>Concomitant medications or diseases states that prolong QT interval or affect electrolytes</li>
<li>history of Qt prolongation</li>
</ol>
<b>Atypical Antipsychotics and Metabolic Effects</b></p>
<p>
<img src="data:image/jpeg;base64,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
"><br>
</p>
<p>Potency of different drugs</p>
<p>NMDA, GABA, </p>
<p>Serequel</p>
<p>Lipid Panel</p>
<table width="180" border="1" cellspacing="2" cellpadding="0">
<tr>
<td><figcaption>Cholesterol</figcaption></td>
<td>150(100-199)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>137(0-149)</td>
</tr>
<tr>
<td>HDL</td>
<td>28</td>
</tr>
<tr>
<td>VLDL</td>
<td>27</td>
</tr>
<tr>
<td>LDL</td>
<td>50</td>
</tr>
</table>
<table id="components688" class="components" summary="Table of test result components"><colgroup><col><col><col></colgroup><thead><tr><th title="Result Component" scope="col" id="components688_col0">Component</th><th title="Value of Component Result" scope="col" id="components688_col1">Your Value</th><th title="Range of Normal Values" scope="col" id="components688_col2">Standard Range</th></tr></thead><tbody><tr class="odd"><td class="nameCol srchbl" headers="components688_col0">LDL Direct</td><td class="valueCol" headers="components688_col1">121<span class="unit"> mg/dL</span></td><td class="rangeCol" headers="components688_col2"><130 mg/dL</td></tr><tr><td class="nameCol srchbl" headers="components688_col0">Total Cholesterol</td><td class="valueCol" headers="components688_col1">180<span class="unit"> MG/DL</span></td><td class="rangeCol" headers="components688_col2">25 - 199 MG/DL</td></tr><tr class="odd"><td class="nameCol srchbl" headers="components688_col0">Triglycerides</td><td class="valueCol" headers="components688_col1">191<span class="unit"> MG/DL</span></td><td class="rangeCol" headers="components688_col2">10 - 150 MG/DL</td></tr><tr><td class="nameCol srchbl" headers="components688_col0">HDL Cholesterol</td><td class="valueCol" headers="components688_col1">29<span class="unit"> MG/DL</span></td><td class="rangeCol" headers="components688_col2">35 - 135 MG/DL</td></tr><tr class="odd"><td class="nameCol srchbl" headers="components688_col0">Total Chol / HDL Cholesterol</td><td class="valueCol" headers="components688_col1">6.2<span class="unit"> </span></td><td class="rangeCol" headers="components688_col2"><4.5</td></tr><tr><td class="nameCol srchbl" headers="components688_col0">Non-HDL Cholesterol</td><td class="valueCol" headers="components688_col1">151<span class="unit"> MG/DL</span></td><td class="rangeCol" headers="components688_col2">MG/DL</td></tr><tr class="odd tableRowMessage comments"><td class="srchbl" colspan="3" headers="components688_col0">TARGET: <(LDL-C TARGET + 30)MG/DL</td></tr><tr class="odd"><td class="nameCol srchbl" headers="components688_col0">Coronary Heart Disease Risk Table</td><td class="valueCol" headers="components688_col1"> </td><td class="rangeCol" headers="components688_col2"> </td></tr><tr class="tableRowMessage comments odd"><td class="srchbl" colspan="3" headers="components688_col0">TOTAL CHOLESTEROL/HDL RATIO:CHD RISK<br>CORONARY HEART DISEASE RISK TABLE<br><br> MEN WOMEN<br>1/2 AVERAGE RISK 3.4 3.3<br>AVERAGE RISK 5.8 4.4<br>2 X AVERAGE RISK 9.6 7.1<br>3 X AVERAGE RISK 23.4 11.0<br><br>Use the calculated Patient Ratio and the CHD Risk Table to determine the patient's CHD Risk.<br><br>ATP III Classification (LDL):<br><100 mg/dl Optimal<br>100-129 mg/dl Near or Above Optimal<br>130-159 mg/dl Borderline<br>160-189 mg/dl High<br>>190 mg/dl Very High</td></tr></tbody></table>
<p>AB = 6<br>
A = 2<br>
B = 3<br>
O = 5</p>
<table class="lists">
<tbody>
<tr>
<th colspan="12">Inherited Blood Type/Donor/Organ Donor/Blood Donation</th>
</tr>
<tr>
<td colspan="2"><b>Parent 1</b></td>
<td><b><span style="color: #961e1b;">AB</span></b></td>
<td><b><span style="color: #961e1b;">AB</span></b></td>
<td><b><span style="color: #961e1b;">AB</span></b></td>
<td><b><span style="color: #961e1b;">AB</span></b></td>
<td><b><span style="color: #961e1b;">B</span></b></td>
<td><b><span style="color: #961e1b;">A</span></b></td>
<td><b><span style="color: #961e1b;">A</span></b></td>
<td><b><span style="color: #961e1b;">O</span></b></td>
<td><b><span style="color: #961e1b;">O</span></b></td>
<td><b><span style="color: #961e1b;">O</span></b></td>
</tr>
<tr>
<td colspan="2"><b>Parent 2</b></td>
<td><b><span style="color: #961e1b;">AB</span></b></td>
<td><b><span style="color: #961e1b;">B</span></b></td>
<td><b><span style="color: #961e1b;">A</span></b></td>
<td><b><span style="color: #961e1b;">O</span></b></td>
<td><b><span style="color: #961e1b;">B</span></b></td>
<td><b><span style="color: #961e1b;">B</span></b></td>
<td><b><span style="color: #961e1b;">A</span></b></td>
<td><b><span style="color: #961e1b;">B</span></b></td>
<td><b><span style="color: #961e1b;">A</span></b></td>
<td><b><span style="color: #961e1b;">O</span></b></td>
</tr>
<tr>
<td colspan="2"><span style="color: #961e1b;"><b>O</b></span></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td colspan="2"><span style="color: #961e1b;"><b>A</b></span></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td style=background:orange>+</td>
<td></td>
<td>+</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td colspan="2"><span style="color: #961e1b;"><b>B</b></span></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td style=background:orange>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td colspan="2"><span style="color: #961e1b;"><b>AB</b></span></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Overdose</p>
<table width="236" border="1" cellspacing="2" cellpadding="0">
<tr>
<td>13607.775mg</td>
<td>450 mg</td>
<td>2mg</td>
<td>5g</td>
<td></td>
<td>800mg</td>
<td>200mg</td>
<td>75mg</td>
<td>70mg</td>
<td>21mg</td>
</tr>
<tr>
<td>ambien(mg)</td>
<td>zyperax(mg)</td>
<td>fentanyl(mcg)</td>
<td>lithium(450g)</td>
<td>Carfentanil
<div data-ved="2ahUKEwi-_sDp3bzcAhVDy1MKHUWnD6UQ3z4oAHoECA0QAw">
<div>
<div data-md="16" data-hveid="CA0QBA" data-ved="2ahUKEwi-_sDp3bzcAhVDy1MKHUWnD6UQhygwEnoECA0QBA">
<div>
<div aria-level="3" role="heading">
<div data-local-attribute="d3bn" data-ved="2ahUKEwi-_sDp3bzcAhVDy1MKHUWnD6UQ3B0oATASegQIDRAN"></div>
</div>
</div>
</div>
</div>
</div>
</td>
<td>Codeine</td>
<td>morphine</td>
<td>herion</td>
<td>Vitamin A</td>
<td>Vitamin D</td>
</tr>
<tr>
<td>5mg</td>
<td>5-10mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</table>
<p>Antipsychotic Side Effects By Receptors Blocked</p>
<table width="343" border="1" cellspacing="2" cellpadding="0">
<tr>
<td>Receptor Type</td>
<td>Side Effects</td>
</tr>
<tr>
<td>D<sub>2</sub></td>
<td>EPS, prolactin elevation</td>
</tr>
<tr>
<td>M<sub>1</sub></td>
<td>Cognitive Deficits, dry mouth, constipation, increased heart rate, urinary retention, blured vision </td>
</tr>
<tr>
<td>α<sub>1</sub></td>
<td>hypotension</td>
</tr>
<tr>
<td>5-HT<sub>2A</sub></td>
<td>Anti-EPS?</td>
</tr>
<tr>
<td>5-HT<sub>2C</sub></td>
<td>Satiety blockade</td>
</tr>
</table>
<p>D = dopamine, EPS = Extra Pyramidal Side Effects, M=muscarine, H=Histamine, 5-HT=serontonin</p>
<p></p>
<p>Diabetes insulin resistent</p>
<p></p>
<p><a href="https://www.statista.com/statistics/242494/leading-prescriptions-dispensed-antipsychotic-drugs-in-the-us/">Top antipsychotics prescribed 2011-2012</a></p>
<p>Mania</p>
<table width="431" border="1" cellspacing="2" cellpadding="0">
<tr>
<td></td>
<td>EPS</td>
<td>Sedation</td>
<td>Weight</td>
<td>Hyperlygemia</td>
<td>Anticholinergic</td>
<td>Othorstatic<br>
hypotension</td>
<td>TD</td>
<td>Hyperprolactinemia </td>
<td>diabetes</td>
<td>cardiac arrhythmias</td>
<td>torsades de pointes</td>
<td>QTc</td>
</tr>
<tr>
<td>Risperidone</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td></td>
<td></td>
<td>+/-</td>
<td></td>
<td>+</td>
<td>low</td>
</tr>
<tr>
<td>Seroquel</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td></td>
<td></td>
<td>+/-</td>
<td>-</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>low</td>
</tr>
<tr>
<td>Clozapine</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solian</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abilify</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Geodon </td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>latuda</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haldol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>remeron</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>high</td>
</tr>
<tr>
<td>elavil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>trazodone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>doxepin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
</table>
<p></p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>14</td>
<td>14</td>
<td>15</td>
<td>17</td>
<td>18</td>
<td>24</td>
<td>27</td>
<td>32</td>
<td>33</td>
<td>33</td>
<td>37</td>
<td>38</td>
</tr>
<tr>
<td>Solian</td>
<td>Paliperidone</td>
<td>Sertindole</td>
<td>Iloperidone</td>
<td>Aripirazole</td>
<td>Lurasidone</td>
<td>Risperidone</td>
<td>Haloperidol</td>
<td>Asenpaine</td>
<td>Olan/apine</td>
<td>Quetiapine</td>
<td>Ziprasidone</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</table>
<p>zyprexa = hyperlipidemia, hyperglycemia</p>
<p>Is diabetes risk solely based on weight or something else?</p>
<p>NMS</p>
<p>For example is it </p>
<table width="595" border="1" cellspacing="2" cellpadding="0">
<tr>
<td>Receptor Type</td>
<td>Adverse Effects</td>
<td>Withdrawal Effects</td>
</tr>
<tr>
<td>Dopamine</td>
<td>EPS, weight gain, endocrine effects, akathisia, TD, increased prolactin, sexual or reproductive system dysfunction</td>
<td>Pychosis, mania, agitation, akathisia, dyskinesia</td>
</tr>
<tr>
<td>Serotonin</td>
<td>Weight gain, diabetes, increased appetite</td>
<td>EPS, akathisia, psychosis, decrease apetite</td>
</tr>
<tr>
<td>Histamine</td>
<td>Weight gain, diabetes, sedation</td>
<td>agitation, insomnia, anxiety, EPS</td>
</tr>
<tr>
<td>Muscarinic</td>
<td>Dry mouth, blurred vision, constipation, urinary retention, diabetes, memory problems, cognitive problems, tachycardia, hypertension</td>
<td>Agitation, confusion, psychosis, anxiety, insomnia, sialorrhea, EPS, akathisia, diarhea, nausea, vomiting, bradycardia, hypotension, syncope</td>
</tr>
<tr>
<td>Adrenergic</td>
<td>Postural hypotension, dizziness, syncope</td>
<td>Tachycardia, hypertension, hypotension, dizziness</td>
</tr>
</table>
<p>Mechanisms behind receptor-mediated psychotropic-induced weight effects</p>
<table width="766" border="1" cellspacing="2" cellpadding="0">
<tr>
<td>Receptor</td>
<td>Activity</td>
<td>Effects/Mechanism</td>
<td>receptor name</td>
</tr>
<tr>
<td>Dopamine-2</td>
<td>Antagonism</td>
<td>Weight gain</td>
<td>d</td>
</tr>
<tr>
<td>Histamine-1</td>
<td>Antagonism</td>
<td>Weight gain</td>
<td>h</td>
</tr>
<tr>
<td>Murscarinic-3</td>
<td>Antagonism</td>
<td>diabetes via glucose tolerance</td>
<td>m</td>
</tr>
<tr>
<td>Serontonin-1A</td>
<td>Partial agonism</td>
<td>migigate weight effects</td>
<td>5-HT<sub>1A</sub></td>
</tr>
<tr>
<td>Serotonin-2C</td>
<td>Antagonism</td>
<td>causes weight gain via disinhibition of hpythalamic neuropeptide Y neurons and inhibition of pro-opiomelanocortin neurons; may also influence leptin restistance</td>
<td>5-HT<sub>2C</sub>
</td>
</tr>
</table>
<p></p>
<p>Relative affinity for H1 Receptors (100)</p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>100</td>
<td>10</td>
<td>4.99</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td>Amitriptyline</td>
<td>Antidepressants</td>
<td>Trazodone</td>
<td></td>
</tr>
</table>
<p>Atypical Agents and Histamine H1 Receptor Blockade</p>
<table border="1" cellspacing="2" cellpadding="0" class="bargraph">
<tr>
<td>7.1</td>
<td>1.7</td>
<td>9.1</td>
<td>14</td>
<td>36</td>
</tr>
<tr>
<td>Benadryl</td>
<td>Risperidone</td>
<td>Seroquel</td>
<td>Zyprexa</td>
<td>Clozapine</td>
</tr>
</table>
<p>EPS = extrapymadil symptoms. Source C Correll, "Assessing and maximizing the safety and tolerability of antipsychotics used in treatment of children and adolescents." J Chin Psychiatry 69, suppl. 4 (2008) 26-36. Also see C. Cornell, "Antipsychotics use in children and adolescents." J Am Acad Child Adols Psychiatry.47 (2008) 9-20</p>
<p>Richmond Agitation Sedation Scale</p>
<p>
“I have struggled with having a mental illness since my teenage years. Currently I am 51 years old. Initially I was diagnosed with depression, but even with medications, my illness worsened, and in time I was having bipolar mood swings and psychotic symptoms.
My illness turned my life upside down and estranged me from my family and friends. In August, 2010, my husband called Dr. Alice Lee-Bloem for help, because I was deteriorating after trying to get off my medications (Lithium, Zyprexa, Prozac, and Lipitor) through “True Hope”, a nutritional company, that had success in using their nutritional products, E. M. Power Plus and other supplements, to help bipolar patients get off their medications long distance. Initially, I had done well, but in time, my mental health deteriorated to the point that I was almost in need of being hospitalized. I was psychotic and unable to sleep. I was also very irritable and paranoid of everyone around me.
Dr. Lee told me to get back on some medication to restabilize me. I was started on Risperdal, and it helped me enough to prevent the need to rehospitalize me. Then she started me on a nutritional regimen and did a lot of energy medicine work on me. Over time, my sleep, mood, and cognitive functions improved, and I was able to start weaning down on my Risperdal. As I came down on Risperdal, I transitioned to a small dosage of liquid Haldol. Eventually, I was able to get off of the Haldol completely as well.
</p><p>I did an analysis, using muscle testing, to check for the patient’s qualitative function, and the results indicated that the patient was on too much medication, not too little. I had been too conservative with the taper and not aggressive enough. This was it. After six months of treatment, we would need to stop the remaining 0.3 mg of Risperdal. To do so would go against my training and would require courage and faith in following the testing results. I shared my results and conclusion with the family and patient, looking a little concerned, worried and apologetic.</p>
Switching Drugs Risperidone
<table width="431" border="1" cellspacing="2" cellpadding="0">
<tbody><tr>
<td></td>
<td>Risperidone</td>
<td>Seroquel</td>
<td>Olanzapine</td>
<td>Clozapine</td>
<td>Solian</td>
<td>Abilify</td>
<td>Geodon</td>
<td>Haldol</td>
<td>Doxepin</td>
<td>Remeron</td>
<td>Elavil</td>
<td>Trazodone</td>
</tr>
<tr>
<td>Risperidone</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td></td>
<td></td>
<td>+/-</td>
<td></td>
<td>+</td>
<td>low</td>
</tr>
<tr>
<td>Seroquel</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>++</td>